Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 24 of the 42 sources its claims cite were checked for support.
Abstract
BACKGROUND: High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, reduces triglyceride levels and improves other lipid levels. METHODS: In a multinational, double-blind, randomized, controlled trial, we assigned patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia (triglyceride level, 200 to 499 mg per deciliter), and high-density lipoprotein (HDL) cholesterol levels of 40 mg per deciliter or lower to receive pemafibrate (0.2-mg tablets twice daily) or matching placebo. Eligible patients were receiving guideline-directed lipid-lowering therapy or could not receive statin therapy without adverse effects and had low-density lipoprotein (LDL) cholesterol levels of 100 mg per deciliter or lower. The primary efficacy end point was a composite of nonfatal myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes. RESULTS: Among 10,497 patients (66.9% with previous cardiovascular disease), the median baseline fasting triglyceride level was 271 mg per deciliter, HDL cholesterol level 33 mg per deciliter, and LDL cholesterol level 78 mg per deciliter. The median follow-up was 3.4 years. As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density lipoprotein (VLDL) cholesterol, -25.6% for remnant cholesterol (cholesterol transported in triglyceride-rich lipoproteins after lipolysis and lipoprotein remodeling), -27.6% for apolipoprotein C-III, and 4.8% for apolipoprotein B. A primary end-point event occurred in 572 patients in the pemafibrate group and in 560 of those in the placebo group (hazard ratio, 1.03; 95% confidence interval, 0.91 to 1.15), with no apparent effect modification in any prespecified subgroup. The overall incidence of serious adverse events did not differ significantly between the groups, but pemafibrate was associated with a higher incidence of adverse renal events and venous thromboembolism and a lower incidence of nonalcoholic fatty liver disease. CONCLUSIONS: Among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, and low HDL and LDL cholesterol levels, the incidence of cardiovascular events was not lower among those who received pemafibrate than among those who received placebo, although pemafibrate lowered triglyceride, VLDL cholesterol, remnant cholesterol, and apolipoprotein C-III levels. (Funded by the Kowa Research Institute; PROMINENT ClinicalTrials.gov number, NCT03071692.).
Overview
CoChat Summary
TL;DR
In the PROMINENT trial, pemafibrate lowered triglyceride and remnant cholesterol levels but did not reduce cardiovascular events among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, low HDL cholesterol, and controlled LDL cholesterol. The trial was stopped early for futility, and pemafibrate was associated with more renal adverse events and venous thromboembolism.
Key findings
- Among 10,497 patients, a primary end-point event occurred in 572 patients in the pemafibrate group and 560 in the placebo group (hazard ratio, 1.03; 95% CI, 0.91 to 1.15; P=0.67), with no apparent effect modification in any prespecified subgroup.
- At 4 months, the relative between-group differences were −26.2% for triglycerides, −25.8% for VLDL cholesterol, −25.6% for remnant cholesterol, and −27.6% for apolipoprotein C-III; apolipoprotein B increased by 4.8%.
- Serious adverse events did not differ significantly overall (1970 vs. 1914; hazard ratio, 1.04; 95% CI, 0.98 to 1.11; P=0.23), but pemafibrate was associated with higher renal adverse events (1463 vs. 1347; hazard ratio, 1.12; 95% CI, 1.04 to 1.20; P=0.004) and venous thromboembolism (71 vs. 35; hazard ratio, 2.05; 95% CI, 1.35 to 3.17; P<0.001), and lower nonalcoholic fatty liver disease (155 vs. 200; hazard ratio, 0.78; 95% CI, 0.63 to 0.96; P=0.02).
Methods
- Multinational, double-blind, randomized, placebo-controlled, event-driven trial conducted at 876 clinical sites in 24 countries; 10,497 patients composed the intention-to-treat population after 41 randomized patients were excluded for Good Clinical Practice violations.
- Eligible patients had type 2 diabetes, fasting triglyceride levels of 200 to 499 mg per deciliter, HDL cholesterol ≤40 mg per deciliter, and LDL cholesterol ≤100 mg per deciliter if they could not receive statins without adverse effects; patients were randomly assigned 1:1 to pemafibrate 0.2-mg tablets twice daily or matching placebo, with median follow-up of 3.4 years.
- The primary efficacy end point was a composite of nonfatal myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes; analysis used a likelihood-ratio test based on a proportional-hazards model stratified by sex, history of cardiovascular disease, and baseline statin use, with analysis of covariance for lipid changes.
Limitations
- The paper states that the data cannot rule out the possibility that observed increases in apolipoprotein B and LDL cholesterol levels in the pemafibrate group negated any benefit of reduction in triglyceride or remnant cholesterol levels.
- The trial was terminated early for futility after 75% of the target number of events had accrued, with median follow-up of 3.4 years; the text notes this termination but does not frame it as a limitation.
- Evident from the text: the trial population was 27.5% women and predominantly white (85.4% in the pemafibrate group and 86.4% in the placebo group), which may limit generalizability; the paper does not state this as a limitation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 6 Not checked · 62 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The data from the PROMINENT trial are consistent with increased efficiency in conversion of triglyceride-rich lipoprotein remnants to LDL rather than their removal by the liver. 21”
What the sources say
- Disputedcites [21] 21. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies - a consensus statement from the European Atherosclerosis Society. Eur Heart J 2021; 42: 4791-806. sourceExperimental — accuracy not yet measured
The “Stimulating lipolysis” section says further insights were awaited from PROMINENT, rather than reporting data from it. The paper discusses conversion of remnants to LDL as a possible consequence of more efficient lipolysis, but does not attribute that finding to PROMINENT. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“With the exception of the FIELD trial, all these trials involved patients who were receiving statins.”
What the sources say
- Partly supportedcites [2] 2. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020; 324: 2268-80. sourceExperimental — accuracy not yet measured
The Study Population section (p. 3) says participants in this trial were required to receive statins, supporting the claim for the STRENGTH trial. It does not establish that every other trial under discussion involved statin-treated patients or that FIELD was the sole exception. (LLM, conf=0.84)
- Partly supportedcites [4] 4. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67. sourceExperimental — accuracy not yet measured
The AIM-HIGH paper reports statin use in its own trial: Table 1, reproduced in the Discussion passage, shows baseline use in 94.4% and 92.8% of the two groups. Our copy does not establish that all the other trials referred to by the citing sentence involved patients receiving statins, or that FIELD was the exception. (LLM, conf=0.83)
- Partly supportedcites [6] 6. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 156374. sourceExperimental — accuracy not yet measured
The Methods (Study Design; page not available) say ACCORD Lipid assigned patients to simvastatin plus fenofibrate or placebo, supporting the claim for this trial. The Discussion (page not available) contrasts ACCORD with FIELD’s statin-therapy drop-in, but does not establish that all the other trials mentioned involved patients receiving statins. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, a previous trial of niacin 4 and two previous trials of fenofibrate 5,6 showed no significant decrease in cardiovascular risk, although triglyceride levels were lowered by 26%, 29%, and 26%, respectively.”
What the sources say
- Partly supportedcites [4] 4. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67. sourceExperimental — accuracy not yet measured
The Discussion reports no significant reduction in cardiovascular events with extended-release niacin added to intensive statin therapy. However, the Lipid Levels section reports a 28.6% triglyceride decrease at two years in the niacin group, not 26%; Table 2 also gives no 26% decrease at years one or three. Our copy does not provide page numbers for these passages. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“although the findings regarding the latter effect of PPARα agonism are less consistent than those regarding increases in the activity of lipoprotein lipase. 17-19”
What the sources say
- Not checked — no full text of the sourcecites [17] 17. Ginsberg HN. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives. Am J Med 1987; 83: 66-70. source
- Not checked — no full text of the sourcecites [18] 18. Watts GF, Barrett PH, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003; 52: 803-11. source
- Supportedcites [19] 19. Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010; 95: 2727-35. source
The Discussion (page unavailable) says fibrates differ in their effects on VLDL secretion and clearance, while describing stimulation of lipoprotein lipase activity as a known fibrate effect. The Results likewise show that fenofibrate reduced VLDL-apoB secretion but did not change hepatic VLDL-TG secretion. Together, these passages support the cited comparison in consistency. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, our data further highlight the complexity of lipid mediators of residual risk among patients with insulin resistance who are receiving statin therapy. 6,23-25”
What the sources say
- Supportedcites [6] 6. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 156374. source
The cited ACCORD Lipid paper provides background for the citing authors’ conclusion, rather than evidence about their own PROMINENT data. Its Results (Plasma Lipids and Clinical Outcomes; page unavailable) report lipid changes with fenofibrate added to simvastatin but no significant overall reduction in cardiovascular events; the Discussion describes a possible benefit in a dyslipidemic subgroup. These findings support the point that lipid-related residual risk in statin-treated patients with type 2 diabetes is complex. (LLM, conf=0.85)
- Supportedcites [23] 23. Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2017; 2: 370-80. source
The reference supports the cited background point, not the citing authors’ statement about their own PROMINENT data. The Introduction describes uncertain cardiovascular benefit from targeting triglycerides and HDL-C in statin-treated patients with type 2 diabetes; the Discussion describes mixed trial results, and the Results report a neutral overall fenofibrate effect but possible benefit in a dyslipidemic subgroup. (LLM, conf=0.88)
- Partly supportedcites [24] 24. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab 2019; 21: 366-71. sourceExperimental — accuracy not yet measured
The Discussion reports that triglyceride levels were associated with residual cardiovascular events in statin-treated patients with diabetes despite controlled LDL cholesterol, supporting the background point about lipid-related residual risk. The study concerns patients with diabetes, not the broader population of patients with insulin resistance. The citing authors’ statement about what their own data highlight is not attributed to this source. (LLM, conf=0.82)
- Partly supportedcites [25] 25. Zhao Y, Xiang P, Coll B, López JAG, Wong ND. Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease. J Diabetes Complications 2021; 35: 107767. Copyright © 2022 Massachusetts Medical Society. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report residual ASCVD risk in statin-treated patients with diabetes and identify lipoprotein(a) as a predictor of recurrent events. This supports a role for lipid-related risk, but the paper studies diabetes rather than insulin resistance broadly and does not establish lipid mediation of that residual risk. The citing sentence’s reference to “our data” is the citing authors’ own conclusion, not a claim about this source. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
44 more claims
Create a free account to see all 81 claims and every source verdict.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 22
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At a median follow-up of 3.4 years, pemafibrate lowered triglycerides by − 26%, VLDL by − 26%, remnant cholesterol by − 26% and ApoC-III by − 28% compared with placebo.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [180]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PROMINENT trial, in people with type 2 diabetes and elevated triglycerides (≥200 mg/dL and low HDL [≤40 mg/dL]), pemafibrate 0.2 mg twice daily reduced triglycerides by 26% but did not reduce the risk of the primary outcome of nonfatal MI, nonfatal stroke, hospitalization for unplanned coronary revascularization, or cardiovascular death (151).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [151]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, pemafibrate did not significantly reduce the risk of MACE (HR 1.03, 95% CI 0.91–1.15).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [180]
The cited source says what the claim attributes to it.
In the citing paper
“Although pemafibrate significantly reduced TGs (–26.2%), VLDL-C, and remnant cholesterol, it did not reduce MACE compared to placebo, likely due to a lack of effect on apoB-containing particle number and modest increases in LDL-C [64, 65].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“Although pemafibrate significantly reduced TGs (–26.2%), VLDL-C, and remnant cholesterol, it did not reduce MACE compared to placebo, likely due to a lack of effect on apoB-containing particle number and modest increases in LDL-C [64, 65].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [64]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effects on Lipid Levels and Other Key Biomarkers · p. 8
“Pemafibrate, as compared with placebo, also had similar effects on changes from baseline to 4 months and over time on levels of measured very-low-density lipoprotein (VLDL) cholesterol (-25.8%)”
§ Effects on Lipid Levels and Other Key Biomarkers · p. 7
“| VLDL cholesterol level, calculated - mg/dl‡ | VLDL cholesterol level, calculated - mg/dl‡ | VLDL cholesterol level, calculated - mg/dl‡ | VLDL cholesterol level, calculated - mg/dl‡ |”
Citations
Cites
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Self-citationNicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., et al. (2020) · JAMA · doi:10.1001/jama.2020.22258 · Cited by 1,028
Self-citationGinsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Self-citationEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Self-citationCombination lipid therapy in type 2 diabetes
(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245
Cited by
Items 401–500 of 728
Trends in vascular dementia-related mortality in the United States from 2005 to 2020
SALMAN, A., Zaide, D. B., Imran, R., Ain, H. U., BHATTI, M. O., Batool, L., Nasir, B. M., TARIQ, L., Ahmad, S., Khakwani, M. S. K., et al. (2025) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.25.06719-5 · Cited by 3
Yamashita, S., Araki, E., Arai, H., Yokote, K., Tanigawa, R., Saito, A., Suganami, H., Minamikawa, S., & Ishibashi, S. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65707 · Cited by 3
Self-citationZambon, A., Gentile, L., Galimberti, F., Manzato, E., Giaccari, A., Sesti, G., Belfiore, A., Norata, G. D., Temporelli, P. L., Frulloni, L., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104214 · Cited by 3
Suzuki, T., Sato, T., Tanaka, M., Nakata, K., Endo, K., Aida, H., Kawaharata, W., Hosaka, I., Umetsu, A., Ogawa, T., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1496671 · Cited by 5
von Eckardstein, A., März, W., & Laufs, U. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1516-2731 · Cited by 4
“Box Zusatzinfo 2) [1, 9, 11, 12] wird häufig als Argument verwendet, um die Kausalität von HDL in der Pathogenese der Atherosklerose infrage zu stellen.”
BackgroundBosomworth, N. J. (2023) · Canadian Family Physician · doi:10.46747/cfp.6907e134 · Cited by 3
Decicco, E., Peterson, E. D., Gupta, A., Gillard, K. K., Sarnes, E., & Návar, A. M. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100604 · Cited by 5
“In contrast, although several studies have shown that fibrates do not lower cardiovascular risk in patients with diabetes [38 – 40], fibrates were the leading non-statin LLT utilized in our population, used by 6.3 % of those not on a statin.”
ResultInfluentialEicosapentaenoic Acid: between Cardiovascular Benefits and the Risk of Atrial Fibrillation
Egalini, F., Rossi, M., Massussi, M., Gaggero, G., Beccuti, G., Benso, A. S., Piepoli, M. F., & Broglio, F. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303280825231122153024 · Cited by 3
“The primary endpoint included a composite of myocardial infarction (MI), ischemic stroke, any revascularization or death from cardiovascular causes [30].”
BackgroundHypertriglyceridemia – a new and important present
Васильевна, Ц. О., Apartseva, N. E., & As, A. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-4-99-111 · Cited by 4
Doi, T., Langsted, A., & Nordestgaard, B. G. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13771 · Cited by 4
Self-citationManaging hypercholesterolaemia
Nelson, A. J., & Nicholls, S. J. (2024) · Australian Prescriber · doi:10.18773/austprescr.2024.006 · Cited by 4
“13 Trials of omega-3 fatty acids in patients with elevated triglyceride concentrations have produced conflicting results.”
BackgroundBiotherapeutic approaches against cardio-metabolic dysfunctions based on extracellular vesicles
Marchal, S., Andriantsitohaina, R., & Martínez, M. C. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167095 · Cited by 3
Residual lipidic risk and atherosclerosis: not that residual
García–Moll, X. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae134 · Cited by 4
Gemfibrozil mitigates caspase-11-driven myocardial pyroptosis in ischemia/reperfusion injury in mice
Marunouchi, T., Kyono, M., Kikuchi, N., & Tanonaka, K. (2025) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2025.100292 · Cited by 7
Santos, R. D., Ray, K. K., Bacquer, D. D., Jennings, C. S., Kotseva, K., Rydén, L., Lip, G. Y. H., Erlund, I., Ganly, S., Vihervaara, T., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119215 · Cited by 5
Self-citationEmerging therapies in dyslipidaemias
Catapano, A. L. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107229 · Cited by 3
Gobeil, É., Bourgault, J., Mitchell, P. L., Houessou, U., Gagnon, É., Girard, A. S., Paulin, A., Manikpurage, H. D., Couture, C., Marceau, S., et al. (2023) · medRxiv · doi:10.1101/2023.05.29.23290580 · Cited by 3
Ishibashi, S., Arai, H., Yokote, K., Araki, E., Watanabe, M., Nakanishi, M., Makinose, Y., Suganami, H., Kurihara, Y., & Yamashita, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64887 · Cited by 3
Self-citationZhang, B., Ma, D., Pei, Z., Ren, Q., & Qiu, J. F. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1503705 · Cited by 4
Chen, Z., Shen, Y., Chen, X., Hu, J., Mao, L., Lan, R., Li, X., Ye, H., Luo, W., Qin, Y., et al. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s542648 · Cited by 3
Htoo, P. T., Paik, J. M., Everett, B. M., Glynn, R. J., Bykov, K., Hahn, G., Liu, J., Wexler, D. J., & Patorno, E. (2025) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2025.112001 · Cited by 4
Self-citationEgom, E. E. A., & Lema, B. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207208 · Cited by 2
“%) but failed to reduce cardiovascular events (HR~1.03, p = 0.67) in patients with type 2 diabetes and hypertriglyceridemia [36].”
InfluentialWang, Y.-X., Lyu, J., Lu, Z., Liu, M., Feng, W.-Y., Xie, Y., & Liu, G. (2025) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-025-4023-6 · Cited by 2
The two faces of cholesteryl ester transfer protein inhibitors
Pirillo, A., & Catapano, A. L. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001017 · Cited by 2
Lipid lowering therapies in chronic kidney disease: A call to action
Ruiz, J. M., Arroyo, D., de Cos, M., Fernández, M. R., Sánchez-Álvarez, E., Bores, P. G., Hernández, J. L., & Corral, P. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120563 · Cited by 4
Targeting Vulnerable Plaques in Coronary Artery Disease: Detecting Risk, Preventing Events
Kakizaki, R., Bär, S., & Räber, L. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02302-y · Cited by 4
“These agents provide greater cardio - vascular risk reduction [ 27, 28 ] and also promote plaque regression and stabilization.”
Amyloid‐beta (1–40) peptide is associated with systemic metabolic health
Sopova, K., Delialis, D., Aivalioti, E., Georgiopoulos, G. A., Athanasopoulos, S., Zervas, G., Konstantaki, C., Sachse, M., Sigl, M., Duerschmied, D., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70171 · Cited by 3
“27,28 Decreased HDL-c levels is an important risk factors for A β and cerebral small vessel disease burdens, 29 while in cognitively normal individuals, increased levels of triglycerides at midlife predict increase of A β accumulation in the brain 20 years later.”
Dyslipidemia management in stroke prevention: An individualized approach
Stefanou, M., Panagiotopoulos, E., Liberopoulos, E. N., Milionis, H. J., Theodorou, A., Mira, K., de Sousa, D. A., Palaiodimou, L., Vlachopoulos, C., Siasos, G., et al. (2026) · International Journal of Stroke · doi:10.1177/17474930261418388 · Cited by 6
Yamashita, S., Araki, E., Arai, H., Yokote, K., Tanigawa, R., Kunitomi, K., Ikegami, K., Suganami, H., Tanahashi, M., Minamikawa, S., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.01.008 · Cited by 3
Self-citationBouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima, A., Serruys, P. W. J. C., Garg, S., McEvoy, J. W., Wood, D., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., et al. (2026) · EuroIntervention · doi:10.4244/eij-d-25-00598 · Cited by 5
Self-citationTriglyceride reduction after MI and major adverse outcomes in SWEDEHEART—insights for future trials
Schubert, J. R., Hagström, E., Westerbergh, J., Leósdóttir, M., & Ray, K. K. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag076 · Cited by 5
Self-citationKatzmann, J. L., & Laufs, U. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01390-7 · Cited by 2
“Despite a 26% triglyceride reduction, no effect on cardiovascular risk was observed, potentially due to the lack of reductions in the total concentration of atherogenic lipoproteins expressed as apolipoprotein B concentra - tion, which increased by 5% [15 ].”
Natsir, R., Halimah, E., Diantini, A., & Levita, J. (2026) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s593168 · Cited by 3
“Retinal microcirculation exhibits similar susceptibility, though in a non-linear fashion.”
Luo, Y., Mou, Y., Li, Z., Liao, B. Z. J., & Wan, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1793532 · Cited by 4
Edwards, A., Singh, P., Shah, V., Chander, V., & Mishra, S. (2026) · Cells · doi:10.3390/cells15060529 · Cited by 5
“Although the PROMINENT trial found that pemafibrate did not reduce major cardiovascular events, it effectively lowered triglyceride and VLDL cholesterol levels [141].”
Rehman, A., Rajdeep, D., Mohnkern, J. D., & Lin, J. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-09846-1 · Cited by 2
“Conventional TG-lowering therapies, including pemafibrate, fenofibrate, niacin, and omega-3 fatty acids, have demonstrated efficacy in reducing TG levels but have failed to show consistent improvements in cardio-vascular outcomes or safety signals [26–29].”
Alcover, S., Ramos-Regalado, L., Muñoz‐García, N., Girón, G. O., Otero, S., López, S., Padró, T., Badimón, L., & Vilahur, G. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag187 · Cited by 4
“Although lower TG levels are associated with reduced ASCVD event risk, most CV outcomes trials of TG-lowering therapies (such as those involving niacin 11,12 and fi-brates 13,14 ) have failed to demonstrate significant reductions in CV endpoints, despite improvements in patients’ lipid profiles.”
Effects of fenofibrate on angiopoietin-like 3/4/8 proteins and apolipoprotein A5
Yang, Y., Smith, S. A., Chen, Y. Q., Li, H., Zhen, E. Y., Sloan, J. H., Siegel, R. W., Qian, Y., Wen, Y., Jung, H., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101050 · Cited by 2
Jiang, R., Rosenblatt, M., Qi, S., Calhoun, V. D., Wang, Q., Wang, P., Wu, J. I. A. H. U. I., Scheinost, D., & Sui, J. (2026) · Science Advances · doi:10.1126/sciadv.aeg4939 · Cited by 2
Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD
Saum, K. L., Pennathur, S., & Kanter, J. E. (2026) · Circulation Research · doi:10.1161/circresaha.126.327361 · Cited by 3
RACING to judgement: weighing the value of pre-specified subgroup analyses
Stone, N. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac782 · Cited by 2
Oxysterol: Residual Lipid Risk for Interventional Cardiology
Abe, S. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed224 · Cited by 2
Recurrent NAFLD post-LT: Sisyphus’ boulder or Proteus’ parable?
Odenwald, M. A., & Rinella, M. E. (2023) · Liver Transplantation · doi:10.1097/lvt.0000000000000161 · Cited by 2
Epidemiology, Control, and Cardiovascular Outcomes of Dyslipidemia in Diabetes
Fan, W., & Wong, N. D. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_32 · Cited by 2
Dyslipidemia in Metabolic Syndrome
Toh, S.-A. E. S., & Lee, M. H. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_58-1 · Cited by 4
Reducing pancreatitis risk in patients with hypertriglyceridemia
MacDonald, B. J., Garrison, S., & Turgeon, R. D. (2023) · Canadian Family Physician · doi:10.46747/cfp.6912849 · Cited by 2
The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias
Tokgözoğlu, L. S., Orringer, C. E., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad837 · Cited by 2
Characteristic points of latest Standards of Medical Care in Diabetes
Bando, H. (2024) · Diabetes research (Edinburgh, Scotland) · doi:10.36502/2024/droa.6185 · Cited by 2
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?
Alnima, T., Smits, M. M., & Hanssen, N. M. J. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000949 · Cited by 3
Apolipoprotein B-48 and late graft failure in kidney transplant recipients
Szili‐Török, T., de Borst, M. H., Soteriou, A., Post, L., Bakker, S. J. L., & Tietge, U. J. F. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae289 · Cited by 2
Jia, H., Zhang, L., Liao, H., Li, Y., Liu, P., Shi, Q., Jiang, B., Zhang, X., Jiang, Y., Nie, Z., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1505234 · Cited by 2
Soukop, J., Kazdová, L., Hüttl, M., Malínská, H., Marková, I., Oliyarnyk, O., Miklánková, D., Gurská, S., Rácová, Z., Poruba, M., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13010212 · Cited by 2
“However, several randomized controlled trials showed that despite a decrease in blood triglyceride levels of approximately 26%, there was no significant decrease in cardiovascular events [15–17].”
Dynamics of HDL-Cholesterol Following a Post-Myocardial Infarction Cardiac Rehabilitation Program
Bertolín‐Boronat, C., Merenciano-Gonzalez, H., Marcos‐Garcés, V., Mas, M. L. M., Alberola, J. I. C., Pérez-Solé, N., López, L., Argente, M. C. E., Reig, M. V., Benito, A. A., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25399 · Cited by 3
Anagnostis, P. G., Rizos, C. V., Liamis, G. L., Rallidis, L. S., Skoumas, I., Kolovou, G. D., Τζιόμαλος, Κ., Skalidis, E. I., Garoufi, A., Kotsis, V., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.017 · Cited by 3
Management of Dyslipidemia in Chronic Kidney Disease
Vedamurthy, D., Sagheer, U., Patel, A., Singh, G., & Kalra, D. K. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00763-y · Cited by 3
“…reduced CV events in CKD patients in observational datasets, a double-blind randomized trial of Pemafibrate (PROMINENT) in diabetic patients with high triglycerides did not show any reduction of cardiovascular outcomes but was associated with a higher incidence of adverse renal events [ 74 , 75 ].”
Luo, S., Yang, S., Li, P., Gu, N., Yang, D., Lu, Z., Lu, Z., Zhao, R., & Shi, B. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.03.010 · Cited by 3
Tanigawa, R., Nakajima, A., Eguchi, Y., Takahashi, H., Loomba, R. S., Suganami, H., Tanahashi, M., & Arai, H. (2025) · JCSM Communications · doi:10.1002/rco2.70002 · Cited by 3
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention
Kamanu, C., & Karalis, D. G. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01283-1 · Cited by 6
de Assis, A. C. R., Rezende, P. C., Hueb, W. A., Neto, A. S., Scudeler, T. L., Garcia, R. M. R., Andrade, V. C., da Silva, M. F., Ribeiro, M. D. O. L., Mocha, M. R., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf192 · Cited by 3
Cross-prevalence of large and small vessels disease in T2DM: overview from a Belgian academic centre
Lurquin, F. O., Petit, E. L., Ahn, S. A., Rousseau, M. F., & Hermans, M. P. (2025) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2025.2524239 · Cited by 2
Recent progress in anti-atherosclerosis strategies and prospective therapeutic targets
Wang, Z., He, X., Bai, H., Feng, D., Qu, Y., Zhang, Y., Lee, R. J., & Sun, Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126122 · Cited by 4
APOC3 inhibition: The strongest case yet for triglyceride targeting
Shapiro, M. D., & Slipczuk, L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.09.006 · Cited by 2
What is really new in triglyceride guidelines?
Hussain, A., Rifai, M. A., Hermel, M., Slipczuk, L. N., & Virani, S. S. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000802 · Cited by 2
Shinozaki, S., Tahara, T., Miura, K., Lefor, A. K., & Yamamoto, H. (2023) · Life · doi:10.3390/life13061327 · Cited by 6
“Furthermore, it also reduces hepatic VLDL cholesterol and triglyceride production [8].”
BackgroundMethodResultInfluentialВалерьевна, Л. А., Геннадьевна, Ф. С., Trubina, L. V., & Sikhvardt, I. E. (2023) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20230403 · Cited by 3
“При этом применение пемафибрата ассоциировалось с более высокой частотой нежелательных явлений со стороны почек, венозной тромбоэмболии и меньшей частотой неалкогольной жировой болезни печени [30].”
Side effects of anti-lipid medications
Kulig, C. E., Wilczynski, J. A., & Zajicek, J. (2023) · Side effects of drugs annual · doi:10.1016/bs.seda.2023.07.009 · Cited by 2
Lee, S., Liu, T., Chung, C. T., Reinhold, J., Vassiliou, V. S., & Tse, G. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00012-7 · Cited by 3
Yamashita, S., Araki, E., Arai, H., Yokote, K., Tanigawa, R., Saito, A., Suganami, H., Minamikawa, S., & Ishibashi, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65001 · Cited by 4
Self-citationHypertriglyceridaemia and cardiovascular mortality: insights from a large-scale study
Patel, H., Grant, J. K., & Martin, S. S. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad391 · Cited by 2
Watts, G. F., & Chan, D. C. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae095 · Cited by 2
Sherratt, S. C. R., Libby, P., Bhatt, D. L., & Mason, R. P. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-41192-2_17 · Cited by 1
Self-citationAbe, S., Nishino, S., Kanaya, T., Sakuma, M., & Toyoda, S. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.01.016 · Cited by 2
Carotid intima-medial thickness in patients with severe hypertriglyceridemia
Ahmad, M., Kennedy, B. A., Son, S., McIntyre, A. D., Lazarte, J., Wang, J., & Hegele, R. A. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.04.001 · Cited by 1
“However, clinical trials of cardiovascular outcomes using TG-lowering agents such as omega-3 fatty acids [15,16], extended-release niacin [17] and fibrates [18] have been equivocal.”
BackgroundMayer, F., Innerhofer, R., Köller, T., & Binder, C. J. (2024) · Learning materials in biosciences · doi:10.1007/978-3-031-64591-4_10 · Cited by 1
Raja, A., Shafique, M. A., Raja, S., Mustafa, M. S., Shuja, M. H., Ahmed, M., Alim Ur Rahman, H., & Asghar, M. S. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001877 · Cited by 1
Malick, W. A., Rosenson, R. S., Naidu, I., & Mechanick, J. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_5 · Cited by 3
Funabashi, S., Kataoka, Y., Nicholls, S. J., Kitahara, S., Makino, H., Matsubara, M., Matsuo, M., Omura‐Ohata, Y., Koezuka, R., Tochiya, M., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.204 · Cited by 6
Masana, L., Torné, P., García–Moll, X., Dalli, E., & Amigó, N. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104199 · Cited by 1
Pediatric Hypertriglyceridemia: Lipoprotein Metabolism, Etiology, and Management
Moriyama, H., & Ham, J. N. (2025) · Current Pediatrics Reports · doi:10.1007/s40124-025-00349-7 · Cited by 3
“Although high profile randomized controlled trials of fibrates in several thousand high-risk patients (the FIELD, ACCORD, and PROMINENT trials) showed reduction of TG levels, they failed to show significant reductions in CVD outcomes [52–54].”
Mondal, S., Chowdhury, A. S., Deb, R., & Sanyal, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00833-x · Cited by 2
“In a large randomised, placebo-controlled trial involving 10,497 patients with type 2 diabetes and mild-to-moderate hypertriglyceridemia, pemafibrate significantly lowered triglycerides, very-low-density lipoprotein (VLDL) cholesterol, remnant cholesterol, and apolipoprotein C-III levels [22].”
Watanabe, M., Nakanishi, M., Shingaki, W., Gunji, R., Makinose, Y., Kanno, T., & Ishibashi, S. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03294-5 · Cited by 2
Self-citationJukema, B. N., van Voorbergen, S., Janssen, S. L. J. E., Eijsvogels, T. M. H., Mingels, A. M. A., Vroemen, W. H. M., Vrisekoop, N., & Koenderman, L. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf137 · Cited by 3
Evidence-based management of diabetic foot problems
Boulton, A. J. M., & Viswanathan, V. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112932 · Cited by 3
Evinacumab Improved the Homozygous Familial Hypercholesterolemia Lipid Metabolism: A Case Report
Matsuda, T., Osaki, Y., Matsumoto, N., Nakajima, R., Murayama, Y., Sugano, Y., IWASAKI, H. O., Mathis, B. J., Sekiya, M., & Shimano, H. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65925 · Cited by 1
“Fibrate therapy has been reported to lower RLP-C values 26-28 ) .”
Bubnova, M. G., Ezhov, M. V., Aronov, D. M., Galyаvich, A. S., Gurevich, V. S., Duplyakov, D. V., Zafiraki, V. K., Karamnova, N. S., Kashtalap, V. V., Konovalov, G. A., et al. (2025) · Cardiosomatics · doi:10.17816/cs688224 · Cited by 1
The role of the PPAR system in diabetic cardiovascular risk and beyond
Ruscica, M., Macchi, C., Corsini, A., & Sirtori, C. R. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000943 · Cited by 1
Hypertriglyceridaemia and elevated cardiovascular risk: will ANGPTL4 inhibition address both?
Katzmann, J. L., & Laufs, U. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf250 · Cited by 1
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
Bergmark, B. A., Marston, N., & Sabatine, M. S. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2515639 · Cited by 1
VLDL cholesterol and ASCVD risk: A population-based study
Balling, M., Roepstorff, O. G., Gerds, T. A., Varbo, A., Langsted, A., Mortensen, M. B., Smith, G. D., Nordestgaard, B. G., & Afzal, S. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.024 · Cited by 1
Self-citationHu, Q., Chen, L., Xing, L., Xu, Y., Xiong, J., & Tang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1720189 · Cited by 1
Xiao, Q., Wang, M., Wang, S., Wang, L., & Ding, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07647-0 · Cited by 3
“In the PROMINENT trial, Pemafibrate, a new selective PPARα modulator, significantly lowered triglyceride and VLDL-C levels, yet no reduction in cardiovascular events was observed [121].”
Liu, H., Wang, K., Ren, Y., Hu, X., Li, M., Wang, T., Xu, M., Lu, J., Bi, Y., & Xu, Y. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02877-7 · Cited by 1
Estándares SEA 2026 para el control global del riesgo vascular
Mostaza, J. M., Pintó, X., Armario, P., Guijarro, C., Masana, L., Real, J. T., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2026) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500889 · Cited by 2
Nakamura, A., Kagaya, Y., Saito, H., Kanazawa, M., Miura, M., Kondo, M., & Endo, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1750308 · Cited by 1
Management von Fettstoffwechselstörungen – DGK-Kommentar zu den Leitlinien der ESC/EAS (2025)
Laufs, U., Husser, O., Landmesser, U., Lüdike, P., März, W., Schirmer, S. H., Wassmann, S., & Weingärtner, O. (2026) · Die Kardiologie · doi:10.1007/s12181-026-00795-7 · Cited by 1
Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes
Wahab, R. A., & Mahmood, W. A. W. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514261422310 · Cited by 2
Niazi, S. K. (2026) · Discover Medicine · doi:10.1007/s44337-026-00578-9 · Cited by 1
Nordestgaard, A. G. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01393-4 · Cited by 3
“…trials, fibrates, omega-3 fatty acids, and niacin have failed to reduce cardiovascular risk in statin-treated indi - viduals with mild-to-moderate hypertriglyceridemia (plasma triglyceride levels of 150 to 500 mg/dL [1.7 to 5.6 mmol/L]) with the exception of icosapent ethyl [ 10–12 , 44–”
InfluentialLu, J., Liu, Y., Guan, Z., Wu, Y. H., Zhao, Y., Lin, Y., Ma, L., Xue, P., & Guan, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-42918-w · Cited by 2
“For example, neuroinflammation and oxidative stress are rapidly activated following IS and are closely linked to dynamic alterations in lipid metabolites 57,58 .”
Metadata
- Authors
- Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., Brinton, E. A., Eckel, R. H., Elam, M. B., Felicio, J. S., Ginsberg, H. N., Goudev, A., Ishibashi, S., Joseph, J., Kodama, T., Koenig, W., Leiter, L. A., Lorenzatti, A. J., Mankovsky, B., Marx, N., Nordestgaard, B. G., Páll, D., Ray, K. K., Santos, R. D., Soran, H., Susekov, A., Tendera, M., Yokote, K., Paynter, N. P., Buring, J. E., Libby, P., & Ridker, P. M.
- Affiliations
- From the Center for Cardiovascular Disease Prevention, Division of Preventive Medicine (A.D.P., R.J.G., J.G.M., E.S.Z., B.M.E., N.P.P., J.E.B., P.M.R) and the Division of Cardiovascular Medicine (B.M.E.,P.L., P.M.R.), Brigham and Women’s Hospital, the Division of Cardiovascular Medicine, Veteran Affairs Boston Health Care System (A.D.P., J.J.), and Kowa Pharma Development (R.O.) — all in Boston; University of Lille, Lille (J.-C.F.) and the Department of Neurology and Stroke Center, Paris Cité University, Paris (P.A.) — both in France; Kowa Research Institute, Morrisville, NC (S.E.C.); the Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa (D.J.B.); Utah Lipid Center, Salt Lake City (E.A.B.); the University of Colorado School of Medicine, Aurora (R.H.E.); the University of Tennessee Health Science Center, Memphis (M.B.E.); the Division of Endocrinology, Universitário Hospital João de Barros Barreto, Belém (J.S.F.), and the Heart Institute (InCor), University of ...
- Brigham and Women's Hospital (US)
- University of Copenhagen (DK)
- ORCID
- Everett, Brendan M.
- Amarenco, Pierre
- Blom, Dirk J.
- Brinton, Eliot A.
- Eckel, Robert H.
- Elam, Marshall B.
- Ginsberg, Henry N.
- Goudev, Assen
- Ishibashi, Shun
- Joseph, Jacob
- Kodama, Tatsuhiko
- Leiter, Lawrence A.
- Lorenzatti, Alberto J.
- Mankovsky, Boris
- Marx, Nikolaus
- Nordestgaard, Børge G.
- Páll, Dénes
- Ray, Kausik K.
- Santos, Raul D.
- Soran, Handrean
- Susekov, Andrey
- Yokote, Koutaro
- Paynter, Nina P.
- Buring, Julie E.
- Libby, Peter
- Ridker, Paul M
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-11-24
- Volume
- 387
- Issue
- 21
- Pages
- 1923-1934
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4308367139
- Semantic Scholar
- 2a5f509a3e50569b803a22d0dee824c145e73e75
- Cited by
- 749
- References
- 25
- Citations by year
- 2026: 153 · 2025: 185 · 2024: 191 · 2023: 208 · 2022: 10
- FWCI
- 142.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Kowa Research Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- pemafibrate, hypertriglyceridemia, type 2 diabetes, PPARα agonist, triglyceride lowering, cardiovascular risk reduction, cardiovascular events, HDL cholesterol, remnant cholesterol, apolipoprotein C-III, apolipoprotein B, VLDL cholesterol, renal adverse effects, venous thromboembolism, lipid-lowering therapy, statin intolerance
- MeSH terms
- Heart Disease Risk Factors, Hypolipidemic Agents, Benzoxazoles, Butyrates, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Humans, Hyperlipidemias, Cholesterol, HDL, Cholesterol, LDL, Risk Factors, Triglycerides, Hypertriglyceridemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors, PPAR alpha, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.